Kinnate Biopharma Incis A Clinical Stage Precision Oncology Company Based In San Diegocaliforniawith Operations In San Franciscothe Company Is Dedicated To Developing Targeted Therapies For Cancers Driven By Specific Genetic Alterationskinnate Designs Selective Small Molecule Inhibitors That Address Unmet Medical Needs In Oncologyparticularly Focusing On Overcoming Treatment Resistance And Non Responsiveness Kinnate S Pipeline Features Several Investigational Therapiesincluding Exarafeniba Pan Raf Inhibitor For Braf And Nras Driven Cancersand Kin 3248An Fgfr Inhibitor Targeting Cancers With Fgfr2 3 Alterationsthe Company Is Also Developing Early Stage Programssuch As A C Met Inhibitor For Resistant Cancer Variants And A Cdk4 Selective Inhibitor For Cancers Dependent On Cdk4 Signalingkinnate Employs A Biomarker Driven Strategy To Identify Patient Subgroups Most Likely To Benefit From Its Therapiesprioritizing Targets With Clear Genetic Driversin February 2024Kinnate Was Acquired By Xoma Corporationenhancing Its Resources To Advance Its Clinical Programs
No conferences found for this company.
| Company Name | Kinnate Biopharma Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
